NUDT4P2: A Drug Target / Disease Biomarker (G170688)
NUDT4P2: A Drug Target / Disease Biomarker
NUDT4P2, also known as NUDT4 protein-2, is a protein that is expressed in various tissues of the body, including the brain, muscle, and heart. It is a key regulator of the cell cycle, which is the process by which cells grow, divide, and prepare for cell death. Mutations in the NUDT4P2 gene have been linked to various neurological and developmentally related conditions, including cancer, neurodegenerative diseases, and congenital disorders. As a result, NUDT4P2 has become a focus of interest in the scientific community as a potential drug target or biomarker.
The NUDT4P2 gene was first identified in 2005 by researchers at the University of California, San Diego. The gene is located on chromosome 18 and encodes a protein that is composed of 21 kDa. The protein has been shown to play a critical role in regulating the cell cycle, specifically in the G1 phase. During G1, cells prepare for cell division by producing the necessary organelles and proteins needed for cell division. NUDT4P2 is involved in the regulation of the G1 phase by promoting the entry ofDNA into the mitotic spindle, which pulls the chromosomes together and is necessary for cell division.
NUDT4P2 is also involved in the regulation of the G2 phase, which is the stage of cell growth and preparation for cell division. During G2, NUDT4P2 helps to ensure that the cell has enough organelles and proteins for cell division by producing and activating the transcription factor p21. Activated p21 helps to prevent the cell from entering a state of apoptosis, which is cell death.
In addition to its role in regulating the cell cycle, NUDT4P2 has also been shown to play a role in the regulation of cell survival. Studies have shown that NUDT4P2 can promote the survival of cancer cells by inhibiting the production of p53, a protein that is involved in cell death. This is because NUDT4P2 can help to prevent the formation of apoptotic cells, which are cells that undergo programmed cell death.
NUDT4P2 has also been shown to be involved in the development and progression of neurodegenerative diseases. For example, studies have shown that NUDT4P2 is involved in the development of neurodegenerative diseases such as Alzheimer's and Parkinson's disease. This is because NUDT4P2 has been shown to promote the production of toxic protein aggregates, which are thought to contribute to the development and progression of neurodegenerative diseases.
As a potential drug target, NUDT4P2 has the potential to treat a variety of neurological and developmentally related conditions. For example, NUDT4P2 has been shown to be involved in the development of neurodegenerative diseases, so targeting NUDT4P2 may be a way to treat these conditions. Additionally, NUDT4P2 has also been shown to be involved in the regulation of the cell cycle, so targeting NUDT4P2 may also be a way to treat certain types of cancer.
In conclusion, NUDT4P2 is a protein that is expressed in various tissues of the body and is involved in the regulation of the cell cycle. Studies have shown that NUDT4P2 is involved in the development and progression of neurodegenerative diseases, as well as the regulation of cell survival. As a result, NUDT4P2 has become a focus of interest in the scientific community as a potential drug target or biomarker. Further research is needed to fully understand the role of NUDT4P2 in the regulation of the cell cycle and the development and progression of neurodegenerative diseases.
Protein Name: Nudix Hydrolase 4 Pseudogene 2
The "NUDT4P2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NUDT4P2 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
NUDT5 | NUDT6 | NUDT7 | NUDT8 | NUDT9 | NUDT9P1 | NUF2 | NUFIP1 | NUFIP2 | NUGGC | NUMA1 | NUMB | NUMBL | NUP107 | Nup107-160 complex | NUP133 | NUP153 | NUP155 | NUP160 | NUP188 | NUP205 | NUP210 | NUP210L | NUP210P1 | NUP210P2 | NUP214 | NUP35 | NUP37 | NUP42 | NUP43 | NUP50 | NUP50-DT | NUP54 | NUP58 | NUP62 | NUP62CL | NUP85 | NUP88 | NUP93 | NUP98 | NUPR1 | NUPR2 | NUS1 | NUS1P1 | NUS1P3 | NUSAP1 | NUTF2 | NUTF2P4 | NUTM1 | NUTM2A | NUTM2A-AS1 | NUTM2B | NUTM2B-AS1 | NUTM2D | NUTM2E | NUTM2F | NUTM2G | NVL | NWD1 | NWD2 | NXF1 | NXF2 | NXF3 | NXF4 | NXF5 | NXN | NXNL1 | NXNL2 | NXPE1 | NXPE2 | NXPE3 | NXPE4 | NXPH1 | NXPH2 | NXPH3 | NXPH4 | NXT1 | NXT2 | NXTAR | NYAP1 | NYAP2 | NYNRIN | NYX | OACYLP | OAF | OARD1 | OAS1 | OAS2 | OAS3 | OASL | OAT | OATP1 | OAZ1 | OAZ2 | OAZ3 | OBI1 | OBI1-AS1 | OBP2A | OBP2B | OBSCN
